BIO-RAD LABORATORIES, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $13.69B | $470.8M |
| FY2022 | $1.20B | $9.62B | $434.2M |
| FY2023 | $1.20B | $8.74B | $403.8M |
| FY2024 | $1.20B | $6.57B | $488.1M |
| FY2025 | $1.20B | $7.45B | $529.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $13.69B | $470.8M |
| FY2022 | $1.20B | $9.62B | $434.2M |
| FY2023 | $1.20B | $8.74B | $403.8M |
| FY2024 | $1.20B | $6.57B | $488.1M |
| FY2025 | $1.20B | $7.45B | $529.8M |